Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

The most common cause of cystic fibrosis (CF) is deletion of phenylalanine 508 (DeltaF508) in the CF transmembrane conductance regulator (CFTR) chloride channel. The DeltaF508 mutation produces defects in folding, stability, and channel gating. To identify small-molecule correctors of defective cellular processing, we assayed iodide flux in DeltaF508-CFTR-transfected epithelial cells using a fluorescent halide indicator. Screening of 150,000 chemically diverse compounds and more than 1,500 analogs of active compounds yielded several classes of DeltaF508-CFTR correctors (aminoarylthiazoles, quinazolinylaminopyrimidinones, and bisaminomethylbithiazoles) with micromolar potency that produced greater apical membrane chloride current than did low-temperature rescue. Correction was seen within 3-6 hours and persisted for more than 12 hours after washout. Functional correction was correlated with plasma membrane expression of complex-glycosylated DeltaF508-CFTR protein. Biochemical studies suggested a mechanism of action involving improved DeltaF508-CFTR folding at the ER and stability at the cell surface. The bisaminomethylbithiazoles corrected DeltaF508-CFTR in DeltaF508/DeltaF508 human bronchial epithelia but did not correct a different temperature-sensitive CFTR mutant (P574H-CFTR) or a dopamine receptor mutant. Small-molecule correctors may be useful in the treatment of CF caused by the DeltaF508 mutation.

[1]  A. Taddei,et al.  Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors , 2004, The Journal of general physiology.

[2]  T. Ma,et al.  Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating* , 2003, Journal of Biological Chemistry.

[3]  H. Wakelee,et al.  Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. , 1996, The American journal of physiology.

[4]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[5]  F. Collins,et al.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. , 1991, Science.

[6]  M. Welsh,et al.  Processing of CFTR bearing the P 574 H mutation differs from wild-type and ∆ F 508-CFTR , 2022 .

[7]  R. Kopito,et al.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. , 1994, The Journal of biological chemistry.

[8]  D. Clarke,et al.  The ΔF508 Mutation Disrupts Packing of the Transmembrane Segments of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2004, Journal of Biological Chemistry.

[9]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[10]  D. Selkoe,et al.  Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases , 2004, Nature Cell Biology.

[11]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[12]  B. Papsin,et al.  Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.

[13]  T. Hwang,et al.  Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms , 1999, Pflügers Archiv.

[14]  H. V. Van Tol,et al.  Folding Efficiency Is Rate-limiting in Dopamine D4 Receptor Biogenesis* , 2005, Journal of Biological Chemistry.

[15]  J. Pilewski,et al.  Role of CFTR in airway disease. , 1999, Physiological reviews.

[16]  G. Rossi,et al.  An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[17]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[18]  M. Welsh,et al.  Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2 , 1991, Molecular and cellular biology.

[19]  T. Hwang,et al.  Genistein potentiates wild-type and delta F508-CFTR channel activity. , 1997, The American journal of physiology.

[20]  J. Sambrook,et al.  The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins , 1988, Nature.

[21]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.

[22]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[23]  J. Riordan,et al.  Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. , 2004, Molecular biology of the cell.

[24]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.

[25]  P. Zeitlin,et al.  In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. , 1997, The Journal of clinical investigation.

[26]  A S Verkman,et al.  Green fluorescent protein‐based halide indicators with improved chloride and iodide affinities , 2001, FEBS letters.

[27]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[28]  Nicoletta Pedemonte,et al.  Phenylglycine and Sulfonamide Correctors of Defective ΔF508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating , 2005, Molecular Pharmacology.

[29]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.

[30]  L. Vetrivel,et al.  High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening* , 2002, The Journal of Biological Chemistry.

[31]  J C Olsen,et al.  Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis , 1992, Nature genetics.

[32]  G. Lukács,et al.  Conformational and Temperature-sensitive Stability Defects of the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum Compartments* , 2001, The Journal of Biological Chemistry.

[33]  A S Verkman,et al.  Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds* 210 , 2001, The Journal of Biological Chemistry.

[34]  M. Welsh,et al.  Processing of CFTR bearing the P574H mutation differs from wild-type and deltaF508-CFTR. , 1999, Journal of cell science.

[35]  M. Welsh,et al.  Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, The EMBO journal.

[36]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[37]  D. Sheppard,et al.  Molecular pharmacology of the CFTR Cl- channel. , 1999, Trends in pharmacological sciences.

[38]  Hong Yang,et al.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. , 2002, The Journal of clinical investigation.